Section 246-945-350 - Collaborative drug therapy agreements(1) A pharmacist exercising prescriptive authority in their practice must have a valid CDTA on file with the commission and their practice location.(2) A CDTA must include: (a) A statement identifying the practitioner authorized to prescribe and the name of each pharmacist who is party to the agreement;(i) The practitioner authorized to prescribe must be in active practice; and(ii) The authority granted must be within the scope of the practitioners' current practice.(b) A statement of the type of prescriptive authority decisions which the pharmacist is authorized to make, which includes: (i) A statement of the types of diseases, drugs, or drug categories involved, and the type of prescriptive authority activity (e.g., modification or initiation of drug therapy) authorized in each case.(ii) A general statement of the training required, procedures, decision criteria, or plan the pharmacist is to follow when making therapeutic decisions, particularly when modification or initiation of drug therapy is involved.(c) A statement of the activities the pharmacist is to follow in the course of exercising prescriptive authority, including: (i) Documentation of decisions made; and(ii) A plan for communication or feedback to the authorizing practitioner concerning specific decisions made.(3) A CDTA is only valid for two years from the date of signing.(4) Any modification of the written guideline or protocol shall be treated as a new CDTA.Wash. Admin. Code § 246-945-350
Adopted by WSR 20-12-072, Filed 6/1/2020, effective 7/1/2020, and 3/1/2021